Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MEG.0000000000002410 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modern pharmacotherapy guidance for treating alcohol use disorders.
Expert Opin Pharmacother
February 2025
Forel Clinic, Addiction Treatment Center, Ellikon, Switzerland.
Introduction: Alcohol use disorder (AUD) is prevalent and recognized as a chronic, relapsing disorder. Even though effective treatment options are available, AUD is strongly undertreated. As adjuvant treatment strategies accompanying psychosocial treatments, pharmacological strategies can increase the efficacy of AUD treatment options.
View Article and Find Full Text PDFPatient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research.
BMJ Open
December 2024
Department of Addictions, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Article Synopsis
- - The systematic review analyzed current qualitative literature on patient experiences with opioid use disorder (OUD) treatments, focusing on opioid agonist, partial agonist, and antagonist medications.
- - Researchers screened 1,129 studies, ultimately including 47 reports published from 2005 to 2023, identifying five major themes related to treatment expectations, medication responses, pharmacy experiences, maintenance support, and social factors influencing treatment.
- - The findings emphasize the need for patient-centered care and integrated healthcare services, highlighting gaps and calling for more qualitative research in real-world environments.
Next-generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.
Alcohol Clin Exp Res (Hoboken)
January 2025
Waggoner Center for Alcohol and Addiction Research, University of Texas at Austin, Austin, Texas, USA.
Article Synopsis
- The review explores the role of various omics-based biomarkers in understanding alcohol and alcohol use disorder (AUD), providing definitions and background on key concepts.
- It highlights four types of omics information: genetic, epigenetic, transcriptomic, and metabolomic, detailing their use as risk and diagnostic biomarkers for AUD and related alcohol consumption.
- Finally, the review discusses the clinical implications of these findings and suggests directions for future research in the field of alcohol studies.
Safety of acamprosate for alcohol use disorder after liver transplant: A pilot randomized controlled trial.
Liver Transpl
April 2025
Department of Internal Medicine, Division of Gastrointestinal & Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Article Synopsis
- Acamprosate is a treatment for people with alcohol problems, but we don't know much about how safe it is for those who have had a liver transplant.
- In a study with 30 participants, some took acamprosate and others received standard care over 14 weeks, looking at side effects and how well the treatment worked.
- The results showed that acamprosate seemed safe and worked just as well as standard care, which is good news for future research on helping liver transplant patients with alcohol issues.
Introduction: Alcohol use is common in patients with chronic hepatitis C virus (HCV) infection. We examined the impact of alcohol use on direct-acting antiviral (DAA) therapy outcome and the clinical course of liver disease and 2-year survival for patients receiving HCV DAA therapy.
Methods: Adults (n = 2624) recruited from 26 Australian hospital liver clinics during 2016-2021 were followed up for 2 years.